Biocept, Inc. (BIOCQ)

OTCMKTS · Delayed Price · Currency is USD

0.0001

0.00 (0.00%)

At close: Mar 5, 2026

0.00% (1Y)

Market Cap	263.00
Revenue (ttm)	1.36M
Net Income (ttm)	-30.61M
Shares Out	2.63M
EPS (ttm)	-44.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	203
Average Volume	3,729
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0001
52-Week Range	0.0000 - 0.1000
Beta	44.82
RSI	47.26
Earnings Date	n/a

About Biocept

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 1997

Employees 50

Stock Exchange OTCMKTS

Ticker Symbol BIOCQ

Full Company Profile

Financial Performance

In 2022, Biocept's revenue was $25.86 million, a decrease of -57.78% compared to the previous year's $61.25 million. Losses were -$32.09 million, 1036.2% more than in 2021.

Financial Statements

News

There is no news available yet.